{"entity":{"id":"nct07623356","kind":"trial","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Ivonescimab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.","summary":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07623356 by Akeso, with 265 participants planned, started 2026-07-07 and due to reach its primary completion in 2028-06-18. Interventions recorded: AK138D1, Ivonescimab, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07623356","url":"https://clinicaltrials.gov/study/NCT07623356"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor"],"targets":[],"drugs":["ivonescimab","carboplatin"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07623356","phase":"1/2","setting":"A Phase Ib/II Study of AK138D1 as Monotherapy and in Combination With Ivonescimab in Patients With Advanced Non-Small Cell Lung Cancer","sponsor":"Akeso","participation":[{"nct":"NCT07623356","source":"https://clinicaltrials.gov/study/NCT07623356","fetchedAt":"2026-10-07T16:55:51.217Z","studySha256":"ce5c8fcf312a9daa0fe7277ce658ff12767b9b7e3d8dc97a664d78bda2e20ba7","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-29","leadSponsor":"Akeso","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":265,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-07-07","startedType":"actual","enrolled":265,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07623356/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}